方盛制药(603998.SH)：2025年中报净利润为1.69亿元

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) reported a decline in revenue and profitability in its 2025 mid-year report, indicating challenges in its operational performance [1] Financial Performance - The company's total revenue for the period was 834 million yuan, a decrease of 76 million yuan compared to the same period last year, representing a year-on-year decline of 8.35% [1] - The net profit attributable to shareholders was 169 million yuan [1] - The net cash inflow from operating activities was 129 million yuan [1] Financial Ratios - The latest debt-to-asset ratio stood at 43.90%, ranking 45th among disclosed peers [1] - The gross profit margin was 70.30%, down 0.20 percentage points from the previous quarter and down 2.36 percentage points year-on-year [1] - The return on equity (ROE) was reported at 10.33% [1] Earnings and Efficiency Metrics - The diluted earnings per share were 0.39 yuan [1] - The total asset turnover ratio was 0.26 times, a decrease of 0.02 times compared to the same period last year, reflecting an 8.56% year-on-year decline [1] - The inventory turnover ratio was 0.65 times, ranking 47th among disclosed peers, and decreased by 0.06 times year-on-year, representing a decline of 7.83% [1]